ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib in previously untreated EGFR exon 20 insertion-mutated NSCLC did not meet its primary endpoint of progression-free survival by blinded independent central review. Investigator-assessed PFS and confirmed objective response rate showed clinical benefit, while an overall-survival improvement trend was observed but remains immature; the safety profile showed no new signals.

Analysis

This is a material de-risking of firmonertinib’s commercial path: a missed BICR primary endpoint is difficult to offset with investigator-assessed PFS or response rate unless the full dataset shows a persuasive, internally consistent benefit. The immature OS trend is optionality, not yet evidence to underwrite approval or a favorable label. Near term, expect the market to discount the program sharply and demand more evidence before assigning value; avoid assuming the entire company is impaired to the same degree without separating firmonertinib from the rest of ArriVent’s pipeline and cash runway.

Competitive positioning in EGFR exon 20 insertion NSCLC shifts toward established treatment choices, including amivantamab-based therapy, unless follow-up demonstrates a meaningful efficacy, tolerability, or convenience advantage. The second-order risk is weaker partnering leverage and potentially less favorable financing terms if investors conclude the pivotal asset needs further work; the extent depends on undisclosed balance-sheet and pipeline data.

Over the next 1–3 months, detailed subgroup, event-count, hazard-ratio, and OS data—and any regulatory feedback—are the key catalysts. Over 6–18 months, a credible OS signal or a viable development strategy could recover some value; absent that, development delays and financing dilution become more salient. Contrarian upside exists if the market treats this as a complete read-through to all assets, but the current release alone does not establish that interpretation.

Key Decisions for Investors

• Do not buy the initial dip on secondary endpoints alone. Wait for the BICR effect size and confidence interval, event counts, prespecified analysis details, and evidence that investigator/BICR discordance has a credible explanation.
• For existing AVBP exposure, reassess position size against verified cash runway and the value of non-firmonertinib programs; consider reducing or hedging rather than treating an immature OS trend as a floor. Those company-level inputs are not provided here.
• Keep AVBP on an event-driven watchlist for full data and regulatory commentary over the next 1–3 months. Revisit a long only if the OS follow-up and totality of evidence support a plausible path forward; thesis is weakened further by an unfavorable agency position, a development pause, or financing on dilutive terms.
• Avoid a short recommendation before checking the post-news price, borrow, cash position, and remaining pipeline value. A sharp selloff could already price in much of the program impairment; a sustained recovery without stronger data would also challenge the bearish thesis.